VTGN סך נכסי הפעילות העסקית VistaGen Therapeutics Inc

This chart of total assets for Vistagen Therapeutics (VTGN), valued at 52.33, highlights the impact of patent protection for nasal anxiety treatments and strict FDA oversight. Vistagen Therapeutics (VTGN) positions itself as a leading developer of safe, fast-acting neuropreparations. The stability of operational processes is ensured through the use of specialized ancillary medical services for the transport of research samples.

The lack of a stable cash flow leaves Vistagen Therapeutics (VTGN) vulnerable to external shocks, meaning the business's margin of safety is determined exclusively by the volume of venture capital raised. By analyzing total asset dynamics, calculated reverse through ROA to eliminate quarterly gaps, an investor assesses the real value of resources and liabilities, which allows for the timely detection of risks associated with the accumulation of illiquid assets.